Wolverine Asset Management’s NovoCure NVCR Stock Holding History

Wolverine Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-102	Closed	-$1.32K	–	1803
2025 Q3	$1.32K	Hold	102	–	–	﹤0.01%	1495
2025 Q2	$1.81K	Hold	102	–	–	﹤0.01%	1486
2025 Q1	$1.82K	Sell	102 -1	-1%	-$23	﹤0.01%	1436
2024 Q4	$3.07K	Hold	103	–	–	﹤0.01%	1457
2024 Q3	$1.61K	Hold	103	–	–	﹤0.01%	1487
2024 Q2	$1.76K	Hold	103	–	–	﹤0.01%	1505
2024 Q1	$1.61K	Sell	103 -8,900	-99%	-$131K	﹤0.01%	1481
2023 Q4	$134K	Hold	9,003	–	–	﹤0.01%	1095
2023 Q3	$145K	Buy	+9,003	New	+$260K	﹤0.01%	1095
2020 Q4	–	Sell	-1,798	Closed	-$200K	–	1817
2020 Q3	$200K	Buy	1,798 +1,494	+491%	+$119K	﹤0.01%	984
2020 Q2	$18K	Sell	304 -4,276	-93%	-$281K	﹤0.01%	1377
2020 Q1	$308K	Buy	+4,580	New	+$362K	﹤0.01%	794

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Wolverine Asset Management's NVCR Position: Q4 2025 in Review

Wolverine Asset Management sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 102 shares — an estimated $1.32K sold.

Wolverine Asset Management first reported a position in NVCR in Q1 2020 and held it in 12 quarters. The position peaked at $308K in Q1 2020. 239 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Wolverine Asset Management reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Wolverine Asset Management sold 102 NovoCure shares in Q4 2025, an estimated $1.32K.
Wolverine Asset Management first reported a position in NovoCure in Q1 2020 and held it in 12 quarters.
Wolverine Asset Management's NovoCure position peaked at $308K in Q1 2020.
239 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Wolverine Asset Management's 13F filing for Q4 2025, filed 2 Feb 2026.